Parkinson’s disease is a chronic, progressive disease the nervous system which causes increasing disability over time5 and worldwide3 affects about 6.5 million people. The state is related by the appearance of diagnosed movement or ‘motor ‘symptoms such as tremors, muscular rigidity, stooped posture and slowness or difficulty in movement6 sildenafil online .
The most common side effects of Stalevo are unwanted or uncontrollable movements , nausea, diarrhea, excessive muscle movements , harmless discoloration of urine, sweat and / or saliva; diminished or slow movements , abdominal pain, dizziness, constipation, fatigue, pain and hallucinations. Some of the serious side effects can result in severe diarrhea, severe dyskinesia, hallucinations, other mental disturbances, orthostatic hypotension , rhabdomyolysis , and symptoms similar to neuroleptic malignant syndrome . – Disclaimer – This press release contains forward-looking statements can be identified by words such as by containing potential, intend, may, similar expressions,ons, or by express or implied discussions regarding potential future regulatory filings or approvals of Stalevo or potential future sales of Stalevo. Such forward-looking statements reflect the current views of Novartis regarding future events , and involve known and unknown risks, uncertainties and other factors that lead to the actual results expressed materially from any future results, performance or achievements expressed or implied by such statements vary. There can be no guarantee that reach achieved in additional markets or for any additional indications in any market or that Stalevo is no certain transactions be approved. In particular, the expectations regarding Stalevo is affected, inter alia, unexpected regulatory actions or delays or government regulation generally, unexpected clinical trial results, including unexpected additional analysis of clinical data or unexpected new clinical data; uncertainties materialize, or or hold patent or other proprietary intellectual property protection, competition in general, increased government, industry and general public pricing pressures; production delays or business interruption generally, and other risks and factors referred to in the current form Novartis AG 20-F on file with the U.S. Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those adopted, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake to update forward-looking statements press release as a press release as a result of new information, future events or otherwise. Read more »